After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was...

In a blog post, former Chairman of Quartet Medicine Inc. (Cambridge, Mass.) Bruce Booth said the biotech is winding down its operations. According to the post, Quartet found "some concerning and unexpected neurologic effects in...

In a blog post, former Chairman of Quartet Medicine Inc. (Cambridge, Mass.) Bruce Booth said the biotech is winding down its operations. According to the post, Quartet found "some concerning and unexpected neurologic effects in...

Quartet Medicine Inc. is developing inhibitors against two enzymes in the peripheral nervous system based on genetic findings that support a novel mechanism for ameliorating chronic neuropathic pain that could be complementary to centrally acting...

Analgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated. Quartet is developing inhibitors of...

Harvard Medical School researchers have shown that resolvins could help treat inflammatory pain without the side effects associated with opioids and COX-2 inhibitors. 1 The findings could open up a new indication for Resolvyx Pharmaceuticals...

Unlike typical biotech startups, which are founded by scientists-turned-entrepreneurs who have already chosen the company's founding assets, Solace Pharmaceuticals Inc. was formed by PureTech Ventures with the idea to pick development programs from a broad...

Researchers published in the Proceedings of the National Academy of Sciences evidence that rAAV-TH and rAAV-GCH1 could be used as combination therapy to treat PD. In a rat model of PD, intrastriatal injection of rAAV-TH...